US-based pharmaceutical firm Ischemix has enrolled the first patient in a Phase IIa trial of its lead compound CMX-2043 to prevent contrast-induced acute kidney injury (CI-AKI) in acute coronary syndrome patients undergoing coronary angiography (the CARIN trial).
CMX-2043 is a chemically-modified, naturally-occurring molecule with an excellent safety profile that has showed efficacy in a prior human clinical trial.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Brigham and Women’s Hospital Heart & Vascular Center Interventional Cardiovascular Programs executive director and CARIN trial lead investigator Deepak Bhatt said: "The CARIN trial presents an exciting opportunity to study the potential of CMX-2043 to treat cardiac patients who are at serious risk of complications."
Around 240 patients will be enrolled in the CARIN trial, which will evaluate the ability of CMX-2043 to prevent CI-AKI.
In the US, approximately 500,000 coronary angiography patients are at high-risk of developing CI-AKI and currently there are no approved drug therapies for the same.
The trial will also seek to confirm the results of its prior Phase IIa trial, where CMX-2043 prevented peri-procedural cardiac injury in patients undergoing a percutaneous coronary intervention (PCI).
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataIschemix intends to announce data from the CARIN trial in mid-2015, when it plans to initiate discussions with prospective corporate partners.
The company believes that CMX-2043 has the opportunity to address indications with in excess of a billion dollars of potential revenues, while producing a net cost savings to the health care system.
